Sam Brusco, Associate Editor11.04.22
Exactech has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its new TriVerse primary knee system.
TriVerse offers cruciate retaining, anterior stabilized, and posterior stabilized constructs. Its insert bearings are exclusively available in highly crosslinked vitamin E-stabilized polyethylene.
Exactech’s chief marketing officer and senior VP of Large Joints Adam Hayden told the press, “The TriVerse primary knee system is positioned to be a powerful addition to Exactech’s portfolio that leverages proven design principles and data from hundreds of thousands of total knee replacement patients.”
TriVerse will also feature a compact set of adjustable mechanical instrumentation with future compatibility planned with the ExactechGPS system. The company expects to begin a limited launch in Q2 2023.
“TriVerse will offer orthopedic surgeons an impactful solution that is developed using proven implant design features, intraoperative flexibility and a straightforward approach,” said Hayden.
TriVerse offers cruciate retaining, anterior stabilized, and posterior stabilized constructs. Its insert bearings are exclusively available in highly crosslinked vitamin E-stabilized polyethylene.
Exactech’s chief marketing officer and senior VP of Large Joints Adam Hayden told the press, “The TriVerse primary knee system is positioned to be a powerful addition to Exactech’s portfolio that leverages proven design principles and data from hundreds of thousands of total knee replacement patients.”
TriVerse will also feature a compact set of adjustable mechanical instrumentation with future compatibility planned with the ExactechGPS system. The company expects to begin a limited launch in Q2 2023.
“TriVerse will offer orthopedic surgeons an impactful solution that is developed using proven implant design features, intraoperative flexibility and a straightforward approach,” said Hayden.